KR101015700B1 - 인삼의 발효방법 및 이로부터 제조된 발효 인삼 - Google Patents
인삼의 발효방법 및 이로부터 제조된 발효 인삼 Download PDFInfo
- Publication number
- KR101015700B1 KR101015700B1 KR1020100090934A KR20100090934A KR101015700B1 KR 101015700 B1 KR101015700 B1 KR 101015700B1 KR 1020100090934 A KR1020100090934 A KR 1020100090934A KR 20100090934 A KR20100090934 A KR 20100090934A KR 101015700 B1 KR101015700 B1 KR 101015700B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- fermented
- vacuum
- fermentation
- ginsenoside
- Prior art date
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 173
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 170
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 170
- 238000000034 method Methods 0.000 title claims abstract description 28
- 241000208340 Araliaceae Species 0.000 title claims abstract 19
- 238000000855 fermentation Methods 0.000 title claims description 32
- 230000004151 fermentation Effects 0.000 title claims description 32
- 238000009461 vacuum packaging Methods 0.000 claims abstract description 10
- 240000006439 Aspergillus oryzae Species 0.000 claims abstract description 7
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims abstract description 7
- 238000001816 cooling Methods 0.000 claims abstract description 6
- 238000005406 washing Methods 0.000 claims abstract description 5
- 241000228136 Aspergillus shirousami Species 0.000 claims abstract description 4
- 241000131386 Aspergillus sojae Species 0.000 claims abstract description 4
- 241000233866 Fungi Species 0.000 claims abstract description 3
- 230000001954 sterilising effect Effects 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 235000015872 dietary supplement Nutrition 0.000 claims description 6
- 241000952054 Rhizopus sp. Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000007872 degassing Methods 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000005022 packaging material Substances 0.000 claims description 3
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 abstract description 4
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 abstract description 4
- 238000005507 spraying Methods 0.000 abstract description 4
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 abstract description 3
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 abstract description 3
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 abstract description 3
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 abstract description 3
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 abstract description 3
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 abstract 3
- 239000002054 inoculum Substances 0.000 abstract 3
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 abstract 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 abstract 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 abstract 1
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 abstract 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 abstract 1
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 abstract 1
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 abstract 1
- 241000235527 Rhizopus Species 0.000 abstract 1
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 abstract 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 abstract 1
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 abstract 1
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 abstract 1
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 abstract 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 abstract 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 abstract 1
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 abstract 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 abstract 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 155
- 229930182494 ginsenoside Natural products 0.000 description 48
- 241000283707 Capra Species 0.000 description 37
- 229940089161 ginsenoside Drugs 0.000 description 27
- 230000000694 effects Effects 0.000 description 20
- 229930182490 saponin Natural products 0.000 description 16
- 235000017709 saponins Nutrition 0.000 description 16
- 150000007949 saponins Chemical class 0.000 description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 12
- 235000002789 Panax ginseng Nutrition 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 6
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 6
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003672 processing method Methods 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- -1 oleanane saponin Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/03—Products from fruits or vegetables; Preparation or treatment thereof consisting of whole pieces or fragments without mashing the original pieces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/16—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by heating loose unpacked materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/36—Freezing; Subsequent thawing; Cooling
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/20—Freezing
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
본 발명에 의하면 진공조건에서 종국균을 분사하여 발효시키는 새로운 인삼의 가공방법을 제공할 수 있으며, 이로부터 얻어지는 발효 인삼은 비발효 인삼과 비교하여 진세노사이드 함량이 현저히 높으며, 구성되는 진세노사이드의 개별 함량에도 차이가 커서 인삼의 생리활성 기능을 극대화시킬 수 있는 효과를 기대할 수 있다.
Description
도 3 내지 4는 본 발명의 실시예 2에 의하여 발효시킨 발효 인삼을 제품화한 사진을 나타낸 것이다.
Ginsenoside | ginsenoside content (%, w/w) | ||||||
Sobaek Mt. (8 year old) |
Sobaek Mt. (11 year old) |
Sobaek Mt. (12 year old) |
Sobaek Mt. (15 year old) |
Kangwon (15 year old) |
PalbongsanⅠ (15 year old) |
PalbongsanⅡ (15 year old) |
|
Rh2 | 0.020 ± 0.001 |
0.016 ± 0.000 |
0.014 ± 0.001 |
0.013 ± 0.000 |
0.029 ± 0.001 |
0.027 ± 0.002 |
0.036 ± 0.002 |
Rh1 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
Rg2 | 0.003 ± 0.001 |
0.003 ± 0.000 |
0.002 ± 0.000 |
0.002 ± 0.000 |
0.003 ± 0.000 |
0.003 ± 0.000 |
0.000 |
Rg3 | 0.000 | 0.000 | 0.003 ± 0.000 |
0.001 ± 0.000 |
0.000 | 0.006 ± 0.000 |
0.000 |
Rg1 | 0.012 ± 0.000 |
0.026 ± 0.000 |
0.024 ± 0.000 |
0.030 ± 0.000 |
0.018 ± 0.000 |
0.018 ± 0.000 |
0.019 ± 0.000 |
Rf | 0.031 ± 0.002 |
0.022 ± 0.000 |
0.010 ± 0.000 |
0.008 ± 0.000 |
0.000 | 0.037 ± 0.001 |
0.000 |
Re | 0.118 ± 0.001 |
0.174 ± 0.008 |
0.082 ± 0.001 |
0.071 ± 0.002 |
0.129 ± 0.002 |
0.134 ± 0.001 |
0.109 ± 0.005 |
Rd | 0.116 ± 0.003 |
0.097 ± 0.008 |
0.064 ± 0.001 |
0.036 ± 0.001 |
0.158 ± 0.001 |
0.478 ± 0.003 |
0.562 ± 0.010 |
Rc+Rb2 | 0.021 ± 0.001 |
0.069 ± 0.001 |
0.013 ± 0.000 |
0.015 ± 0.001 |
0.020 ± 0.001 |
0.051 ± 0.010 |
0.030 ± 0.003 |
Rb1 | 0.106 ± 0.003 |
0.394 ± 0.009 |
0.175 ± 0.002 |
0.351 ± 0.008 |
0.163 ± 0.003 |
0.181 ± 0.006 |
0.180 ± 0.003 |
Totala ) ginsenoside |
0.429 ± 0.008 |
0.800 ± 0.010 |
0.386 ± 0.004 |
0.526 ± 0.005 |
0.520 ± 0.006 |
0.936 ± 0.018 |
0.936 ± 0.014 |
PD/PTb ) | 1.598 ± 0.024 |
2.565 ± 0.138 |
2.279 ± 0.014 |
3.752 ± 0.111 |
2.475 ± 0.029 |
3.871 ± 0.062 |
6.268 ± 0.187 |
Rb1/Rg1 | 8.689 ± 0.183 |
15.273 ± 0.432 |
7.273 ± 0.036 |
11.590 ± 0.233 |
9.243 ± 0.233 |
10.185 ± 0.376 |
9.324 ± 0.285 |
a) Sum of individual ginsenosides content b) Ginsenoside Rb1+Rb2+Rc+Rd+Rg3+Rh2 / Re+Rf+Rg1+Rg2+Rh1 Values represent the mean±S.E. (n=3) |
content | Average (%, w/w) | Variance | Statistic significance | |||||
4 years old | 6 years old | woods grown ginseng | 4 years old | 6 years old | woods grown ginseng | F-value | P-value | |
TSa ) | 0.270 ± 0.024 |
0.280 ± 0.027 |
0.648 ± 0.090 |
0.005 | 0.005 | 0.051 | 56.322 | 0.000 |
PD/PTb ) | 2.456 ± 0.286 |
2.183 ± 0.119 |
3.258 ± 0.587 |
0.707 | 0.112 | 2.221 | 7.326 | 0.001 |
Rb1/Rg1 | 3.514 ± 0.239 |
4.865 ± 0.786 |
10.225 ± 0.978 |
0.644 | 5.079 | 6.285 | 75.834 | 0.000 |
Rb1 | 0.060 ± 0.007 |
0.087 ± 0.013 |
0.222 ± 0.040 |
0.000 | 0.001 | 0.010 | 46.981 | 0.000 |
Rb2+Rc | 0.015 ± 0.002 |
0.017 ± 0.002 |
0.031 ± 0.008 |
0.000 | 0.000 | 0.000 | 10.212 | 0.000 |
Rd | 0.070 ± 0.012 |
0.048 ± 0.008 |
0.216 ± 0.080 |
0.001 | 0.000 | 0.041 | 14.809 | 0.000 |
Re | 0.051 ± 0.007 |
0.054 ± 0.005 |
0.117 ± 0.013 |
0.000 | 0.000 | 0.001 | 58.661 | 0.000 |
Rf | 0.013 ± 0.002 |
0.014 ± 0.002 |
0.015 ± 0.006 |
0.000 | 0.000 | 0.000 | 0.432 | 0.651 |
Rg1 | 0.017 ± 0.002 |
0.020 ± 0.004 |
0.021 ± 0.002 |
0.000 | 0.000 | 0.000 | 1.127 | 0.330 |
Rg2 | 0.001 ± 0.001 |
0.000 | 0.002 ± 0.000 |
0.000 | 0.000 | 0.000 | 12.625 | 0.000 |
Rg3 | 0.000 | 0.000 | 0.001 ± 0.001 |
0.000 | 0.000 | 0.000 | 10.257 | 0.000 |
Rh1 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
Rh2 | 0.043 ± 0.004 |
0.040 ± 0.002 |
0.022 ± 0.003 |
0.000 | 0.000 | 0.000 | 34.926 | 0.000 |
a) Sum of individual ginsenosides content b) Ginsenoside Rb1+Rb2+Rc+Rd+Rg3+Rh2 / Re+Rf+Rg1+Rg2+Rh1 F-value of the reject is 3.130 Values represent the mean±S.E. |
Pump : Waters 1525 Binary HPLC Autosampler : Waters 717plus Detector : Waters 2487 Dual λ Absorbance column : Eurospher 100-5 C18 (250*3mm) 이동상 : 물 아세토니트릴 Flow rate : 0.8ml/1min run time : 180 min inject vol (ul) : 10ul 검출기 : 측정파장 203nm conditions : gradient |
Ginsenosides | Ginsenosides contents(%,w/w) | |||
시료-1 | 시료-2 | 시료-3 | 시료-4 | |
Rg1 | 0.018352 ± 0.001916 |
0.088746 ± 0.03554 |
0.023209 ± 0.00702 |
0.004003 ± 0.001431 |
Re | 0.012654 ± 0.002627 |
0.005041 ± 0.004409 |
0.019031 ± 0.008988 |
0.007202 ± 0.008362 |
Rf | 0.049803 ± 0.003659 |
0.02591 ± 0.002565 |
0.1177 ± 0.002546 |
0.044263 ± 0.001488 |
Rb1 | 0.132656 ± 0.012002 |
0.055177 ± 0.010045 |
0.426439 ± 0.00757 |
0.142056 ± 0.019665 |
Rg2 | 0.207618 ± 0.054943 |
0.039369 ± 0.002542 |
0.242473 ± 0.179548 |
0.123794 ± 0.004045 |
Rh1 | 0.049796 ± 0.04333 |
0.113032 ± 0.005633 |
0.19406 ± 0.001184 |
0.067989 ± 0.002056 |
Rc | 0.068664 ± 0.006203 |
0.015132 ± 0.026209 |
0.160801 ± 0.001915 |
0.053721 ± 0.00078 |
Rb2 | 0.064334 ± 0.005392 |
0.037553 ± 0.0134 |
0.150369 ± 0.001674 |
0.058098 ± 0.00475 |
Rd | 0.213099 ± 0.01873 |
0.048966 ± 0.004128 |
0.339392 ± 0.007567 |
0.124015 ± 0.001727 |
Rg3 | 0.298992331 ± 0.031694677 |
0.258502685 ± 0.015396526 |
0.666201423 ± 0.008355937 |
0.222156675 ± 0.003598683 |
PPT | 0.063213 ± 0.009392 |
0.012662 ± 0.021932 |
0.04478 ± 0.077561 |
0 |
compound K | 0.007016533 ± 0.006076497 |
0 | 0 | 0 |
Rh2 | 0.034611 ± 0.004053 |
0.020126 ± 0.004062 |
0.074974 ± 0.001014 |
0.04258 ± 0.002769 |
PPD | 0.078179 ± 0.005647 |
0.074643 ± 0.003629 |
0.16345 ± 0.002297 |
0.073038 ± 0.003528 |
조사포닌 | 33.635 | 44.955 | 41.925 | 40.4 |
진세노사이드 | 8년근 비발효 산양삼 |
8년근 발효 산양삼 |
변화량(%) | 증,감여부 |
Rg1 | 0.012± 0.000 | 0.5477± 0.0140 | 4464 | 증가 |
Re | 0.118± 0.001 | 0.5246± 0.0050 | 344 | 증가 |
Rf | 0.031± 0.002 | 0.1448± 0.0026 | 367 | 증가 |
Rb1 | 0.106± 0.003 | 0.5100± 0.0129 | 381 | 증가 |
Rg2 | 0.003± 0.001 | 1.0505± 0.0380 | 349 | 증가 |
Rh1 | 0.000 | 0.0871± 0.0100 | 새로생성 | 증가 |
Rc+Rb2 | 0.021± 0.001 | 1.1442± 0.0483 | 5348 | 증가 |
Rd | 0.116± 0.003 | 0.5519± 0.0286 | 375 | 증가 |
Rg3 | ||||
PPT | 0.0156± 0.0076 | 새로생성 | 증가 | |
compound K | ||||
Rh2 | 0.020± 0.001 | 0.0018± 0.0014 | 1011 | 감소 |
PPD |
진세노사이드 | 6년근 비발효 인삼 |
6년근 발효 인삼 |
변화량(%) | 증,감여부 |
Rg1 | 0.3143± 0.0024 | 0.5113± 0.0302 | 63 | 증가 |
Re | 0.1123± 0.0020 | 0.4451± 0.0166 | 296 | 증가 |
Rf | 0.0429± 0.0012 | 0.0690± 0.0515 | 61 | 증가 |
Rb1 | 0.1805± 0.0289 | 0.3503± 0.0160 | 92 | 증가 |
Rg2 | 0.1845± 0.0218 | 0.7921± 0.0539 | 329 | 증가 |
Rh1 | 0.0077± 0.0046 | 0.0497± 0.0133 | 545 | 증가 |
Rc | 0.0033± 0.002 | 0.0216± 0.0056 | 554 | 증가 |
Rb2 | 0.1050± 0.0023 | 0.3059± 0.0267 | 190 | 증가 |
Rd | 0.0265± 0.0004 | 0.2745± 0.0051 | 936 | 증가 |
Rg3 | ||||
PPT | 0.0046± 0.0001 | 4600 | 증가 | |
compound K | ||||
Rh2 | 0.0141± 0.0001 | 0.0011± 0.0011 | 1181 | 감소 |
PPD |
Pump : Waters 1525 Binary HPLC, Autosampler : Waters 717plus, Detector : Waters 2487 Dual Absorbance, column : YMC-pack pro C-18 RS (250*4.6mm), 이동상 : 물 아세토니트릴, Flow rate : 1ml/1min, run time : 110 min, inject vol (ul) : 10ul , 검출기 : 측정파장 203nm, conditions : gradient |
진세노사이드 | (%,w/w) | ||||
4년근 발효 인삼 |
6년근 발효 인삼 |
8년근 발효 산양삼 |
6년근 비발효 인삼 |
6년근 홍삼 |
|
Rg1 | 0.4771± 0.0302 | 0.5113± 0.0226 | 0.5477± 0.0140 | 0.3143± 0.0024 | 0.4492± 0.0016 |
Re | 0.4884± 0.0256 | 0.4451± 0.0166 | 0.5246± 0.0050 | 0.1123± 0.0020 | 0.1421± 0.1172 |
Rf | 0.1018± 0.0073 | 0.0690± 0.0515 | 0.1448± 0.0026 | 0.0429± 0.0012 | 0.0735± 0.0531 |
Rb1 | 0.4997± 0.0327 | 0.3503± 0.0160 | 0.5100± 0.0129 | 0.1805± 0.0289 | 0.1855± 0.1560 |
Rg2 | 0.6641± 0.0444 | 0.7921± 0.0539 | 1.0505± 0.0380 | 0.1845± 0.0218 | 0.2485± 0.2118 |
Rh1 | 0.0528± 0.0046 | 0.0497± 0.0133 | 0.0871± 0.0100 | 0.0077± 0.0046 | 0.0350± 0.0094 |
Rc | 0.0051± 0.0007 | 0.0216± 0.0056 | 0.0244± 0.0066 | 0.0033± 0.0002 | 0.1332± 0.2260 |
Rb2 | 0.3310± 0.0269 | 0.3059± 0.0267 | 0.5923± 0.0197 | 0.1050± 0.0023 | 0.1532± 0.1270 |
Rd | 0.3501± 0.0200 | 0.2745± 0.0051 | 0.5519± 0.0286 | 0.0265± 0.0004 | 0.0558± 0.0301 |
Rg3 | 0 | 0 | 0 | 0 | 0.0391± 0.0343 |
PPT | 0.0386± 0.0032 | 0.0046± 0.0001 | 0.0156± 0.0076 | - | 0.0445± 0.0114 |
Rh2 | 0.0068± 0.0017 | 0.0011± 0.0011 | 0.0018± 0.0014 | 0.0141± 0.0001 | - |
Total saponin |
3.0155 | 2.8252 | 4.0507 | 0.9911 | 1.5596 |
Claims (7)
- 인삼을 세척하고 종국균을 분사하여 배양시키는 단계;
상기 배양된 인삼을 진공포장하는 단계;
상기 진공포장된 인삼을 발효시키는 단계; 및
상기 발효된 인삼을 60 내지 65 ℃에서 30 내지 60 분간 가열살균한 다음 4 내지 10 ℃로 급속냉각하여 이루어지는 간헐살균법으로 살균한 후 냉각시키는 단계
를 포함하여 이루어지는 것을 특징으로 하는 인삼의 발효방법.
- 청구항 1에 있어서,
상기 종국균은 아스퍼질러스 오리제(Aspergillus oryzae), 아스퍼질러스 소제(Aspergillus sojae), 아스퍼질러스 시로우사미(Aspergillus shirousamii), 라이조푸스속(Rhizopus sp.), 및 접합균(Zygomycetes) 중에서 선택된 1 종 또는 2 종 이상의 혼합 균류로 이루어지는 것을 특징으로 하는 인삼의 발효방법.
- 청구항 1에 있어서,
상기 배양은 35 내지 45 ℃의 온도, 60 내지 85 %RH의 습도 조건에서 1 내지 4 시간동안 수행되는 것을 특징으로 하는 인삼의 발효방법.
- 청구항 1에 있어서,
상기 발효는 20 내지 60 ℃ 의 온도조건에서 168 내지 336 시간동안 수행되는 것을 특징으로 하는 인삼의 발효방법.
- 청구항 1에 있어서,
상기 발효가 이루어진 인삼의 진공포장된 포장재에 공기 구멍을 내고, 이를 다시 가스제거제가 부착된 진공팩에 넣어 진공포장하는 단계가 추가적으로 포함되는 것을 특징으로 하는 인삼의 발효방법.
- 청구항 1 내지 5 중에서 선택된 어느 한 항의 방법으로 제조된 것을 특징으로 하는 발효 인삼.
- 청구항 1 내지 5 중에서 선택된 어느 한 항의 방법으로 제조된 발효 인삼을 포함하는 건강보조 식품.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100090934A KR101015700B1 (ko) | 2010-09-16 | 2010-09-16 | 인삼의 발효방법 및 이로부터 제조된 발효 인삼 |
CN2011100453756A CN102397309A (zh) | 2010-09-16 | 2011-02-24 | 人参的发酵方法及从中制得的发酵人参 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100090934A KR101015700B1 (ko) | 2010-09-16 | 2010-09-16 | 인삼의 발효방법 및 이로부터 제조된 발효 인삼 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100055166A Division KR100997054B1 (ko) | 2010-06-11 | 2010-06-11 | 산양삼의 발효방법 및 이로부터 제조된 발효 산양삼 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101015700B1 true KR101015700B1 (ko) | 2011-02-22 |
Family
ID=43777597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100090934A KR101015700B1 (ko) | 2010-09-16 | 2010-09-16 | 인삼의 발효방법 및 이로부터 제조된 발효 인삼 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101015700B1 (ko) |
CN (1) | CN102397309A (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101476931B1 (ko) * | 2013-10-16 | 2014-12-24 | 경희대학교 산학협력단 | 신규 류코노스톡 메센테로이데스 thk-d433t 및 이를 이용한 사포닌의 저분자화 방법 |
KR101659974B1 (ko) * | 2016-01-21 | 2016-11-16 | 손미례 | 백국균 발효를 이용한 발효흑삼 추출물의 제조방법 및 상기 방법으로 제조된 발효흑삼 추출물 |
KR102074810B1 (ko) | 2019-08-12 | 2020-02-07 | 김보식 | 가공인삼의 제조방법 및 이에 의해 제조된 가공인삼 |
KR20200073857A (ko) * | 2018-12-14 | 2020-06-24 | 대한민국(농촌진흥청장) | 아스퍼질러스 시로우사미(Aspergillus shirousamii)를 이용하여 도라지의 플라티코시드 E 함량을 증진시키는 방법 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102846685A (zh) * | 2012-09-25 | 2013-01-02 | 吉林省宏久生物科技股份有限公司 | 一种发酵法提高人参果总皂苷含量的制备技术及方法 |
CN103205365B (zh) * | 2013-03-27 | 2014-05-21 | 沈阳药科大学 | 塔宾曲霉及其在制备人参皂苷Rh4及其苷元中的应用 |
CN104435031B (zh) * | 2013-09-17 | 2018-02-02 | 王晓航 | 一种黑人参的加工方法 |
CN103966105B (zh) * | 2013-11-28 | 2017-08-11 | 河南科技学院 | 一种转化人参皂苷Rg3生产Rh2的米曲霉、生产方法及应用 |
CN104825515B (zh) * | 2015-05-15 | 2018-05-29 | 吉林农业大学 | Kefir粒发酵人参粉 |
CN107348511B (zh) * | 2017-08-21 | 2018-04-06 | 东方红(通化)生物医药股份有限公司 | 一种具有辅助降血压作用的西洋参/人参提取物的发酵提取方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050026762A (ko) * | 2003-09-09 | 2005-03-16 | 구성학 | 발효된인삼을이용한고추장제조방법 |
KR20060063517A (ko) * | 2004-12-06 | 2006-06-12 | 송인철 | 인삼 추출액을 이용한 분말청국장 발효법 |
KR20070044598A (ko) * | 2005-10-25 | 2007-04-30 | 구성학 | 발효된 인삼을 이용한 고추장 및 제조 방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100997054B1 (ko) * | 2010-06-11 | 2010-11-30 | 홍진석 | 산양삼의 발효방법 및 이로부터 제조된 발효 산양삼 |
-
2010
- 2010-09-16 KR KR1020100090934A patent/KR101015700B1/ko active IP Right Grant
-
2011
- 2011-02-24 CN CN2011100453756A patent/CN102397309A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050026762A (ko) * | 2003-09-09 | 2005-03-16 | 구성학 | 발효된인삼을이용한고추장제조방법 |
KR20060063517A (ko) * | 2004-12-06 | 2006-06-12 | 송인철 | 인삼 추출액을 이용한 분말청국장 발효법 |
KR20070044598A (ko) * | 2005-10-25 | 2007-04-30 | 구성학 | 발효된 인삼을 이용한 고추장 및 제조 방법 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101476931B1 (ko) * | 2013-10-16 | 2014-12-24 | 경희대학교 산학협력단 | 신규 류코노스톡 메센테로이데스 thk-d433t 및 이를 이용한 사포닌의 저분자화 방법 |
KR101659974B1 (ko) * | 2016-01-21 | 2016-11-16 | 손미례 | 백국균 발효를 이용한 발효흑삼 추출물의 제조방법 및 상기 방법으로 제조된 발효흑삼 추출물 |
KR20200073857A (ko) * | 2018-12-14 | 2020-06-24 | 대한민국(농촌진흥청장) | 아스퍼질러스 시로우사미(Aspergillus shirousamii)를 이용하여 도라지의 플라티코시드 E 함량을 증진시키는 방법 |
KR102169156B1 (ko) | 2018-12-14 | 2020-10-22 | 대한민국 | 아스퍼질러스 시로우사미(Aspergillus shirousamii)를 이용하여 도라지의 플라티코시드 E 함량을 증진시키는 방법 |
KR102074810B1 (ko) | 2019-08-12 | 2020-02-07 | 김보식 | 가공인삼의 제조방법 및 이에 의해 제조된 가공인삼 |
Also Published As
Publication number | Publication date |
---|---|
CN102397309A (zh) | 2012-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101015700B1 (ko) | 인삼의 발효방법 및 이로부터 제조된 발효 인삼 | |
KR100997054B1 (ko) | 산양삼의 발효방법 및 이로부터 제조된 발효 산양삼 | |
KR101697146B1 (ko) | 큰엉겅퀴로부터 실리마린의 고효율 추출하는 방법 | |
KR101482873B1 (ko) | 액체 발효에 의한 황칠 발효 대사체 및 그 제조방법 | |
KR102001740B1 (ko) | 진세노사이드 F2, Rg3 및 컴파운드 케이 고함량 숙취 예방 및 해소용 액상조성물 및 그 제조방법 | |
KR101463979B1 (ko) | 꾸지뽕나무의 열매, 잎, 줄기와 신선초를 이용한 발효음료 및 이의 제조방법 | |
KR20170141497A (ko) | 황칠나무와 한약재료의 효소 추출물을 이용하는 탈모개선 샴푸의 제조 방법 | |
EP3075384A1 (en) | Anti-obesity composition | |
KR101718323B1 (ko) | 발효옻 추출물을 포함하는 위염, 위궤양, 십이지장 궤양, 위암 및 위점막 손상 예방 및 치료용 약학적 조성물 | |
KR20160130651A (ko) | 아로니아와 오디를 이용한 항당뇨 및 시력 개선용 조성물 | |
CN108309922A (zh) | 一种三花发酵原浆化妆品及其制备方法 | |
KR20120036425A (ko) | 케피어 그레인을 사용한 산양삼의 발효방법 및 이로부터 제조된 발효 산양삼 | |
KR101372400B1 (ko) | 미량 진세노사이드의 함량을 증진시킨 홍삼전분의 제조 방법 | |
KR20140058845A (ko) | 황금 및 인삼을 복합 발효시킨 황금삼의 제조 방법 | |
KR102128411B1 (ko) | 산양삼 숙성액 및 이의 제조방법 | |
KR102094084B1 (ko) | 인체 흡수형 진세노사이드 및 오메가-6 지방산이 증진된 산양삼 숙성 복합발효물 및 그 제조방법 | |
KR101018064B1 (ko) | 포장 대추차 제조방법 및 이에 의해 제조된 포장 대추차 | |
KR20140072421A (ko) | 항스트레스용 조성물 | |
KR20170013170A (ko) | 알코올성 간 손상 예방 기능성 성분을 포함하는 인삼열매 추출물 및 그 제조 방법 | |
CN106281842A (zh) | 蓝靛果酒的制备方法 | |
KR101760184B1 (ko) | 곰팡이 균사체 접종에 의해 글리세올린 함량이 증가된 콩의 제조 방법 | |
KR102364062B1 (ko) | 활성산양삼을 함유하는 항염증 조성물 및 그 제조방법 | |
KR101962893B1 (ko) | 갈색거저리 또는 번데기를 이용하여 배양된 동충하초 추출물을 포함하는 조성물 및 그 제조 방법 | |
KR102557683B1 (ko) | 진세노사이드 Rg3 및 프로토파낙사디올, 루틴, 클로로제닉산, 및 필수아미노산이 강화된 산양삼새싹 송이버섯균사체 발효조성물 및 그 제조방법 | |
KR20230065499A (ko) | 진세노사이드 F3, Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 강화된 산양삼새싹 버섯균사체 발효조성물 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140213 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150211 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151124 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161202 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180118 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191126 Year of fee payment: 10 |